Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 5 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ASAPHARM from Gembloux, company number BE0645733354, closed financial year 2025 with a result of € 139,678 after tax. For that financial year ASAPHARM recorded a gross margin of € 97,106 and equity of € 160,138. Compared with financial year 2024, the result moved from € 122,045 to € 139,678. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 160,138
▼ 37% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 139,678
▲ 14% vs 2024
Profit after tax over the fiscal year.
€ 6,694
▼ 90% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 231,910 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 15,304
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.3 million
▲ 38% vs 2024
€ 136,408 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 5,427
▲ € 5,008 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 13,202
▲ 99% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 62,031 | € 46,299 | € 55,265 | € 97,106 | ▲ 76% |
| Profit after taxes | € -7,166 | € 108,722 | € 122,045 | € 139,678 | ▲ 14% |
| Equity | € 45,603 | € 130,325 | € 252,370 | € 160,138 | ▼ 37% |
| Total debts | € 1,208,693 | € 1,148,056 | € 1,050,437 | € 1,700,722 | ▲ 62% |
| Cash | € 18,862 | € 19,148 | € 65,868 | € 6,694 | ▼ 90% |
| Land & buildings | € 341,516 | € 333,032 | € 324,548 | € 316,064 | ▼ 3% |
| Retained profit | € 27,003 | € 111,725 | € 233,770 | € 141,538 | ▼ 39% |
| Dividend | € 41,176 | € 24,000 | € 0 | € 231,910 | |
| Bank debt | € 1,117,710 | € 1,029,277 | € 940,032 | € 1,297,802 | ▲ 38% |
| Balance sheet total | € 1,254,296 | € 1,278,381 | € 1,302,808 | € 1,860,860 | ▲ 43% |
Key figures of ASAPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ASAPHARM?
What happened at ASAPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 139,678 (▲ 14% vs 2024). Source: NBB ↗
- New establishment in Gembloux. KBO
- Start of the company according to the CBE. KBO
In short
From € 7,166 loss in 2022 to € 139,678 profit in 2025.
Paid € 32,568 in corporate taxes since 2022.
Best year ever: 2025, with € 139,678 profit.
Paid out € 297,087 in dividends to the owners in total.
A new publication or filing at ASAPHARM? We notify you, reason included.
Follow ASAPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ASAPHARM is ANDRE LAMBERT ARNAUD. It owns 100% of Pharmacie Barbay and 50% of Pharmacie Themans itself.
Directors
According to the 2025 annual accounts
ANDRE LAMBERT ARNAUD
Director
Establishments
Establishment units
Physical locations of this company
Rue du Petit-Leez, Gd-L. 42
5031 Gembloux
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0645.733.354
- VAT number
- BE 0645.733.354
- Registered office
- Rue du Petit-Leez, Gd-L. 42, 5031 Gembloux
- Names & denominations
- ASAPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 January 2016
- Peppol
- Active · Active since 12 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten